BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MarylandBusiness Wire • 08/04/21
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match ProgramBusiness Wire • 08/03/21
Amazon, Mastercard, Pinterest and More Friday Afternoon Analyst Upgrades and Downgrades24/7 Wall Street • 07/30/21
Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV FranchiseBenzinga • 07/30/21
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MDBusiness Wire • 07/19/21
Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV PatientsBenzinga • 07/19/21
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve AdultsBusiness Wire • 07/17/21
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid InhibitorBusiness Wire • 07/17/21
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021Business Wire • 07/15/21
Investing $72,036 Into These 3 Stocks Can Generate $300 in Monthly Income for Your PortfolioThe Motley Fool • 07/14/21
Gilead's Remdesivir Fails To Show Antiviral Effects Against COVID-19 In Small WHO StudyBenzinga • 07/13/21